Drugs / SYHA1813
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06157918 | Dec 2023 → Jan 2024 | — | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06682611 | Nov 2024 → Nov 2026 expected | — | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06739213 | Jan 2025 → Jan 2027 expected | meningioma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07613450 | May 2026 → Jul 2029 expected | meningioma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-03 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1813 ORAL SOLUTIONS" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the “ Board”) of CSPC Pharmaceutical Group Limited (the “ Company ”, together with its subsidiaries, the “ Group”) is pleased to announce that the Group’s Category 1 innovative drug “SYHA1813 Oral Solutions” (the “ Product ”) has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-03 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1813 ORAL SOLUTIONS" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHA1813 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06739213 ↗ |
| Route | Oral | “SYHA1813 oral solution, 25mg, oral” NCT06157918 ↗ |